MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2174/1574886318666230614164607

Медицинская библиотека · Current drug safety · 2024

Development of Dermatomyositis after Pfizer BioNTeh COVID-19 Vaccine: A Case Report.

Aouintia Imen, Daly Wiem, Lakhoua Ghozlane, Kaabi Widd, Charfi Ons, Debbeche Sana, Kastalli Sarrah, Zaiem Ahmed, El Aidli Sihem

Клинический случайСтатьяПеревод в очереди

Аннотация

INTRODUCTION

The Coronavirus Disease 2019 (COVID-19) pandemic led to the fast development of vaccines, which is considered a medical advance in healthcare. With the extensive vaccination campaign performed worldwide, many adverse events following immunization (AEFI) were reported. Most of them were flu-like symptoms, mild and self-limiting. However, serious adverse events, such as dermatomyositis (DM), an idiopathic autoimmune connective tissue disease, have also been reported.

CASE PRESENTATION: In this report, we describe a case of skin erythema, edema, and diffuse myalgia attributed at first to Pfizer BioNTeh, COVID-19 vaccination, given the temporal relationship and the absence of significant medical history. The causality assessment score was I1B2. However, after completing the etiological assessment, an invasive breast carcinoma was identified, and we retained the diagnosis of paraneoplastic DM.

CONCLUSION

This study underlines the importance of completing the etiological assessment before attributing any adverse reaction to vaccination to maintain optimal patient care.

Для цитирования: Aouintia Imen, Daly Wiem, Lakhoua Ghozlane, Kaabi Widd, Charfi Ons, Debbeche Sana, Kastalli Sarrah, Zaiem Ahmed, El Aidli Sihem. Development of Dermatomyositis after Pfizer BioNTeh COVID-19 Vaccine: A Case Report.. Current drug safety. 2024. DOI: 10.2174/1574886318666230614164607.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.